When Parents Become the Lab: How Family-Led Funding Is Rewriting the Timeline for Rare Disease Research
Photo: Jozef Geirnaert, Public domain, via Wikimedia Commons
When a child receives a diagnosis for a condition so rare it may affect fewer than a few thousand Americans, families often discover two uncomfortable truths at once. First, there may be no established treatment. Second, there may be no researcher actively working toward one. For decades, the standard advice was to wait — for pharmaceutical interest, for federal grant cycles, for a breakthrough somewhere in a distant laboratory. Increasingly, American families have decided they cannot afford to wait.
The Gap That Sparked a Movement
Of the roughly 7,000 diseases classified as rare in the United States, fewer than 10 percent have an FDA-approved treatment. The economics are unforgiving: drug development can cost hundreds of millions of dollars, and companies naturally gravitate toward conditions with larger patient populations. Federal funding through the NIH remains vital, but competition is intense and rare conditions frequently lose out to research with broader commercial promise.
Into that gap has stepped a distinctive American institution: the family-founded nonprofit. From cystic fibrosis to spinal muscular atrophy, some of the most consequential research advances of the past two decades began with parents organizing bake sales, gala dinners, and online crowdfunding campaigns to bankroll the science themselves. The story of spinal muscular atrophy is often cited as proof of concept — family-driven fundraising helped push gene therapy from an idea to an approved treatment that has changed the trajectory of a once uniformly devastating diagnosis.
From Fundraisers to Funding Strategy
What distinguishes today's family-led research efforts is not merely the fundraising, but the sophistication that follows it. Parents are hiring scientific advisors to review grant applications. They are building patient registries that give researchers the data infrastructure needed to design trials. Some are directly sponsoring natural history studies — the unglamorous but essential groundwork that must exist before a trial can enroll a single participant.
Consider the typical arc. A family receives a diagnosis. Within months, they have connected with a handful of researchers worldwide. Within a year or two, they may have incorporated a foundation, recruited a scientific advisory board, and issued their first request for proposals. It is, in effect, a venture capital model applied to rare disease — with a portfolio of one and an urgency no institutional investor can match.
The results can be measured in time. Research that once took a decade to move from laboratory bench to early-phase trial has, in several family-funded programs, been compressed to a fraction of that. Families bring something else institutional funders sometimes lack: direct access to affected communities, which accelerates recruitment and ensures studies are designed around what patients actually need.
Where The Kristen Foundation Fits
The Kristen Foundation's grant program was designed with this ecosystem in mind. Rather than duplicating the work of family foundations, our grants are structured to bridge the gap between their urgency and the formal requirements of academic science. In practice, that means three things.
First, we fund pilot studies — small, early-stage projects that generate the preliminary data researchers need to compete for larger federal awards. These are precisely the projects that traditional funders are least likely to support and that family foundations, often limited in resources, struggle to sustain alone.
Second, we invest in shared infrastructure: patient registries, biobanking, and data coordination that no single family foundation can afford to build but from which many can benefit.
Third, we support the often-overlooked costs of participation in clinical trials — travel, lodging, lost wages — because a trial that families cannot practically attend is a trial that cannot succeed.
The Road Ahead
The rise of patient-powered science raises fair questions. Volunteer-run foundations must guard against conflicts of interest, ensure research is reviewed with genuine rigor, and avoid allowing hope to outrun evidence. The most credible family foundations have embraced independent scientific review precisely because their credibility with researchers — and with regulators — depends on it.
Still, the broader lesson is difficult to dispute. When families are given the tools to fund and shape research, the pipeline moves faster, and it moves toward the questions that matter most to patients. At The Kristen Foundation, we believe the future of rare disease research will not be written by families or institutions alone, but by the partnerships between them. Our commitment is to keep showing up as that partner — grant by grant, study by study, family by family.
